Alkermes (NASDAQ:ALKS) Given New $40.00 Price Target at Mizuho

Alkermes (NASDAQ:ALKS) had its target price boosted by equities researchers at Mizuho from $35.00 to $40.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s price objective points to a potential upside of 41.09% from the stock’s current price.

Several other equities analysts have also commented on ALKS. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and upped their price objective for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. HC Wainwright restated a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a report on Friday, October 25th. StockNews.com upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. JPMorgan Chase & Co. decreased their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, The Goldman Sachs Group decreased their price objective on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Alkermes currently has an average rating of “Moderate Buy” and an average target price of $35.42.

Alkermes Stock Down 3.0 %

Shares of NASDAQ ALKS opened at $28.35 on Wednesday. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The stock has a market cap of $4.59 billion, a PE ratio of 14.91, a P/E/G ratio of 0.98 and a beta of 0.47. The company has a 50-day moving average of $27.73 and a 200 day moving average of $26.18. Alkermes has a 12-month low of $22.06 and a 12-month high of $32.88.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 58,996 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the completion of the sale, the executive vice president now owns 83,300 shares in the company, valued at $2,505,664. This represents a 41.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.89% of the stock is owned by company insiders.

Institutional Trading of Alkermes

Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Alkermes by 421.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company’s stock valued at $225,393,000 after purchasing an additional 6,730,671 shares during the period. Armistice Capital LLC lifted its stake in shares of Alkermes by 301.5% in the second quarter. Armistice Capital LLC now owns 2,699,179 shares of the company’s stock valued at $65,050,000 after purchasing an additional 2,026,961 shares during the period. Loomis Sayles & Co. L P lifted its stake in shares of Alkermes by 365.5% in the third quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company’s stock valued at $52,704,000 after purchasing an additional 1,478,422 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Alkermes by 31.8% in the second quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company’s stock valued at $135,939,000 after purchasing an additional 1,362,079 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Alkermes by 87.1% in the second quarter. American Century Companies Inc. now owns 2,203,456 shares of the company’s stock valued at $53,103,000 after purchasing an additional 1,025,905 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.